f-arag
Small moleculeexperimentalImaging agent
Clinical trial activity
3 trials · 6 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started May 1, 2017 (NCT03129061)
Timeline
2010s
- Jan 1, 2017
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Unspecified targetRadiopharmaceutical
radiopharmaceutical
Chemistry & pharmacology
Loading structure…
SMILES
Nc1nc(O)c2ncn([C@@H]3O[C@H](CO)[C@@H](O)[C@@H]3F)c2n1- Mol. weight
- 285.24 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Imaging
- 18-fluorine
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL3143549 ↗
Also known as
- f-arag
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07076862 | Early Phase 1 (Phase 1) | Dec 31, 2025 | National Institute of Allergy and Infectious Diseases (NIAID), University of California, Davis, University of California, San Francisco |
| NCT07168785 | Early Phase 1 (Phase 1) | Oct 1, 2025 | CellSight Technologies, Inc., Indiana University |
| NCT03129061 | Phase 1 | May 1, 2017 | CellSight Technologies, Inc., Stanford University |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (6)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| CellSight Technologies, Inc. | For profit | 2 | 1 | 1 | 2017 |
| Indiana University | Academic/Hospital | 1 | 1 | 1 | 2025 |
| National Institute of Allergy and Infectious Diseases (NIAID) | Government | 1 | 0 | 1 | 2025 |
| Stanford University | Academic/Hospital | 1 | 0 | 1 | 2017 |
| University of California, Davis | Academic/Hospital | 1 | 1 | 1 | 2025 |
| University of California, San Francisco | Academic/Hospital | 1 | 0 | 1 | 2025 |
6 organizations
Page 1 / 1